1. What Is the Pancreatic Neuroendocrine Tumor Market?
The Pancreatic Neuroendocrine Tumor Market covers therapeutics, diagnostics, and interventional procedures for neoplasms arising from pancreatic islet cells with variable malignant potential and distinct biology from exocrine pancreatic adenocarcinoma. Pancreatic NET encompasses somatostatin analogue therapy, peptide receptor radionuclide therapy, everolimus, sunitinib, and surgical resection for localised disease. Market dynamics reflect pNET incidence growth from improved imaging, PRRT lutetium-177 dotatate achieving commercial adoption, and liquid biopsy NETest enabling circulating tumour marker monitoring.
2. Pancreatic Neuroendocrine Tumor Market Size & Forecast
3. Emerging Technologies
- Next-generation somatostatin analogue formulations with extended release profiles beyond monthly injection are advancing as patient adherence tools. Growing development is driven by monthly injection burden reduction requirements.
- Alpharadin radium-223 combination with PRRT for bone metastatic NET are advancing as combination therapy tools. Growing clinical development is driven by bone metastasis management requirements in advanced NET.
- Telotristat ethyl serotonin synthesis inhibitor for carcinoid syndrome symptom control are advancing as symptom management tools. Growing adoption at carcinoid syndrome patients is driven by diarrhoea and flushing control requirements.
- AI pathology NET grading systems automating Ki-67 proliferation index counting from digital pathology slides are advancing as diagnostic tools. Growing adoption at pathology labs is driven by NET grading standardisation requirements.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Companion Diagnostic Market.
4. Key Market Opportunity
The largest addressable opportunity within the Pancreatic Neuroendocrine Tumor Market is the PRRT Lutathera sub-market, where Novartis achieves growing revenue from PRRT standard-of-care adoption in somatostatin receptor-positive advanced NET. Somatostatin analogue therapy creates a large recurring revenue channel as first-line Somatuline and Sandostatin maintain multi-billion-dollar NET market dominance. Liquid biopsy NETest creates a diagnostic monitoring revenue opportunity as disease surveillance reduces expensive imaging frequency. Asia Pacific pNET creates geographic expansion as Japanese, Chinese, and South Korean NET treatment programme investment and incidence detection grow.
5. Top Companies in the Pancreatic Neuroendocrine Tumor Market
The following organisations hold leading positions in the Pancreatic Neuroendocrine Tumor Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novartis (Lutathera, Sandostatin)
- Ipsen (Somatuline)
- Pfizer (Sunitinib)
- Novartis (Everolimus)
- Advanced Accelerator Applications
- Wren Laboratories (NETest)
- Lexicon Pharmaceuticals (Telotristat)
- Pendopharm
- Camurus
- Sun Pharmaceutical
6. Market Segmentation
The Pancreatic Neuroendocrine Tumor Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Treatment | Somatostatin Analogue PRRT Lutetium-177 Everolimus Sunitinib Surgery |
| By Grade | Grade 1 Well-Differentiated Grade 2 Grade 3 High-Grade |
| By Stage | Localised Regional Metastatic |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Pancreatic Neuroendocrine Tumor Market trajectory over the forecast period:
Novartis Lutathera PRRT Achieves USD 600 Million Annual Revenue as Standard-of-Care for Advanced pNET.Novartis Lutathera lutetium-177 dotatate achieving USD 600 million annual sales in 2024 and NETTER-1 trial establishing PRRT as standard-of-care for somatostatin receptor-positive midgut NET demonstrates radiopharmaceutical therapy commercial leadership. Lutathera expansion into pancreatic NET indication based on NETTER-2 data demonstrating 72 percent progression-free survival improvement validates PRRT as second-line pNET standard.
Ipsen Somatuline and Novartis Sandostatin Achieve Combined USD 2 Billion Annual NET SSA Revenue.Ipsen Somatuline autogel and Novartis Sandostatin LAR achieving combined USD 2 billion annual revenue as somatostatin analogue first-line NET therapy demonstrates SSA market leadership. Somatuline achieving 60 percent of global NET SSA market and Sandostatin 40 percent demonstrate duopoly in first-line NET growth inhibition therapy.
NETest Liquid Biopsy Achieves Clinical Adoption for pNET Disease Monitoring Without Imaging.Wren Laboratories NETest multi-gene liquid biopsy achieving 97 percent sensitivity for neuroendocrine tumour disease activity demonstrates liquid biopsy utility in NET surveillance. NETest adoption at 200-plus NET specialist centres for quarterly disease monitoring demonstrates clinical validation of blood-based NET tumour marker beyond chromogranin A.
For related market intelligence, see the Gallbladder Cancer Market.
8. Segmental Analysis
By treatment, the Somatostatin Analogue segment dominated the Pancreatic Neuroendocrine Tumor Market in 2025. Representing the largest revenue category as first-line Somatuline and Sandostatin generate the majority of NET pharmaceutical revenue. The PRRT Lutetium-177 segment is the fastest-growing category, advancing as Lutathera expands from midgut NET to pancreatic NET indication based on NETTER-2 data.
By grade, the Grade 1 and Grade 2 Well-Differentiated segment dominated in 2025 as the SSA and PRRT-eligible population.
By disease stage, the Metastatic segment dominated the Pancreatic Neuroendocrine Tumor Market in 2025, as the majority of pNET patients present with metastatic disease requiring systemic therapy generating the largest therapeutic revenue. Localised stage is the fastest-growing category, driven by improving surveillance imaging identifying smaller asymptomatic pNETs earlier, expanding the surgical and ablative intervention addressable population.
9. Regional Analysis
Regional demand patterns across the Pancreatic Neuroendocrine Tumor Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Pancreatic Neuroendocrine Tumor Market in 2025, holding 44.7% of the global market. Academic medical centres, NET specialist clinical programmes, and pharmaceutical companies are advancing pancreatic neuroendocrine tumour research, clinical trial activity, and targeted therapy development across the region's strong oncology ecosystem. FDA rare disease drug approval programmes and growing pharmaceutical investment in somatostatin receptor-targeting therapies for NET are encouraging research and clinical development. High rare disease research investment, established NET clinical expertise, and strong pharmaceutical company commitment to neuroendocrine oncology are generating regional treatment development activity.
Highest CAGR Region
Europe is expected to register the highest CAGR of 13.08% during the forecast period. Oncology clinical researchers, academic medical centres, and pharmaceutical companies across Germany, France, the Netherlands, and Italy are conducting significant pancreatic NET research, clinical trial activity, and therapeutic innovation. European Medicines Agency approval pathways and growing pharmaceutical investment in peptide receptor radionuclide therapy for NET are encouraging European clinical development. Strong academic oncology research infrastructure, established NET clinical expertise, and growing rare cancer therapeutic investment are generating European pancreatic NET market development.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Pancreatic Neuroendocrine Tumor Market was valued at USD 1.78 Bn in 2025 and is projected to reach USD 4.71 Bn by 2034, growing at a CAGR of 11.4% over the 2026–2034 forecast period.
The Pancreatic Neuroendocrine Tumor Market is projected to grow at a CAGR of 11.4% from 2026 to 2034.
North America accounted for the largest share of the Pancreatic Neuroendocrine Tumor Market in 2025, holding 44.7% of the global market.
The leading companies in the Pancreatic Neuroendocrine Tumor Market include Novartis (Lutathera, Sandostatin), Ipsen (Somatuline), Pfizer (Sunitinib), Novartis (Everolimus), Advanced Accelerator Applications, Wren Laboratories (NETest), Lexicon Pharmaceuticals (Telotristat), Pendopharm, Camurus, Sun Pharmaceutical.
Novartis lutathera prrt achieves usd 600 million annual revenue as standard-of-care for advanced pnet.
By treatment, the Somatostatin Analogue segment dominated the Pancreatic Neuroendocrine Tumor Market in 2025.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 3 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.